metabolic disease

Ascendis Licences Proprietary Technology to Novo Nordisk

Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop, manufacture, and commercialize proprietary products for the treatment of metabolic and cardiovascular diseases.

News

Pfizer and Wave Life Sciences in Metabolic Diseases Pact

News

AstraZeneca to buy ZS Pharma for $2.7 billion

Top-Feature

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

From Lab to Market Challenge

Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.